TABLE 1.
Patient characteristics
| All | Normal | Abnormal | p-value | |
| Subjects n | 112 | 33 | 79 | |
| Age years, mean±sd | 55.2±17.2 | 52.6±16.5 | 56.3±17.5 | 0.30 |
| Women | 72 (64) | 25 (76) | 47 (59) | 0.10 |
| Biopsy site n (lung/extra-lung) | 99/13 | 30/3 | 69/10 | 0.58 |
| Steroid n (yes/no) | 11/101 | 3/30 | 8/71 | 0.87 |
| Involved organ(s) | ||||
| Eye | 73 (65) | 21 (64) | 52 (66) | 0.82 |
| LN | 105 (94) | 31 (94) | 74 (94) | 0.96 |
| Lung | 77 (69) | 23 (70) | 54 (68) | 0.89 |
| Skin | 22 (20) | 5 (15) | 17 (22) | 0.44 |
| Liver | 5 (4) | 2 (6) | 3 (4) | 0.60 |
| Number of involved organ(s) except for heart, mean±sd | 2.69±0.95 | 2.70±0.95 | 2.68±0.95 | 0.95 |
| Positive FDG PET consistent with CS | 51 (46) | 9 (27) | 42 (53) | 0.012 |
| Positive LGE-CMR consistent with CS | 70 (63) | 14 (42) | 56 (71) | 0.005 |
| Diagnosis of CS | 49 (44) | 6 (18) | 43 (54) | 0.0004 |
Data presented as n (%) unless otherwise stated. LN: lymph node; FDG PET: 18F-fluorodeoxyglucose positron emission tomography; CS: cardiac sarcoidosis; LGE-CMR: late gadolinium-enhanced cardiac magnetic resonance imaging.